Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $42.50.

GMAB has been the subject of a number of recent research reports. Guggenheim upped their target price on Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a report on Monday. New Street Research set a $43.00 price target on Genmab A/S in a research note on Wednesday, July 22nd. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and boosted their price target for the stock from $32.00 to $43.00 in a report on Wednesday, July 22nd. HC Wainwright upped their price objective on Genmab A/S from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $36.65 on Thursday. Genmab A/S has a one year low of $23.62 and a one year high of $40.17. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company has a market cap of $22.87 billion, a price-to-earnings ratio of 28.86, a PEG ratio of 2.05 and a beta of 0.81. The firm has a 50 day simple moving average of $33.30 and a 200 day simple moving average of $29.22.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Research analysts predict that Genmab A/S will post 1.21 earnings per share for the current fiscal year.

Trending Headlines about Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Strong Epkinly trial results: Genmab and partner AbbVie reported that epcoritamab (Epkinly) combined with R-CHOP reduced the risk of disease progression or death by 51% in a Phase 3 frontline DLBCL study, meeting the trial’s primary progression-free survival goal. The result strengthens the drug’s potential in a large first-line market. AbbVie, Genmab’s Epcoritamab Plus R-CHOP Improves PFS In DLBCL
• Positive Sentiment: Potential commercial upside: Commentary on the results said Epkinly’s efficacy compares favorably with Roche’s Polivy in a similar setting and could support Genmab’s existing $3 billion-plus peak-sales outlook, or potentially lead to estimates above that level. Genmab: Epkinly Shines In Phase 3 DLBCL Trial
• Positive Sentiment: Analyst target increases: Truist raised its price target from $40 to $45 and maintained a Buy rating, while HC Wainwright increased its target from $40 to $50 and also rated the shares Buy. These revisions signal greater confidence in Genmab’s pipeline and earnings potential.
• Positive Sentiment: Momentum and estimates: Genmab’s shares recently advanced 10.7% on heavier-than-normal volume, while favorable earnings-estimate revisions suggest analysts may continue to raise forecasts following the DLBCL data. Strength Seen in Genmab
• Neutral Sentiment: Board compensation approved: Genmab’s extraordinary general meeting approved restricted stock-unit grants to board members as compensation. The awards are routine governance-related remuneration, though investors may monitor the resulting share dilution. Genmab To Issue Restricted Stock Units To Board Members

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently modified their holdings of GMAB. Juncture Wealth Strategies LLC lifted its holdings in shares of Genmab A/S by 42.0% during the third quarter. Juncture Wealth Strategies LLC now owns 10,424 shares of the company’s stock worth $372,000 after purchasing an additional 3,083 shares during the period. Versant Capital Management Inc raised its position in Genmab A/S by 4.5% during the 3rd quarter. Versant Capital Management Inc now owns 12,235 shares of the company’s stock worth $436,000 after purchasing an additional 523 shares during the last quarter. QRG Capital Management Inc. raised its position in Genmab A/S by 10.4% during the 2nd quarter. QRG Capital Management Inc. now owns 72,643 shares of the company’s stock worth $1,996,000 after purchasing an additional 6,821 shares during the last quarter. WINTON GROUP Ltd lifted its holdings in Genmab A/S by 158.9% during the 2nd quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock worth $1,124,000 after buying an additional 25,100 shares during the period. Finally, Engineers Gate Manager LP bought a new stake in shares of Genmab A/S in the 2nd quarter valued at about $360,000. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.